ArticleJournal of clinical orthopaedics and trauma2025
Improving outcomes in paediatric high-grade osteosarcoma: Insights from a retrospective survival study.
Article in Journal of clinical orthopaedics and trauma, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: High-grade osteosarcoma is the most prevalent primary malignant bone tumor in children and adolescents. Despite advancements in chemotherapy and surgical techniques, survival rates have stagnated, particularly in patients presenting with metastases or poor chemotherapeutic response. This study aims to evaluate survival outcomes and identify prognostic factors influencing overall survival in pediatric osteosarcoma patients treated at a tertiary care center. Methods: This retrospective cohort study included patients ≤18 years with histologically confirmed high-grade osteosarcoma treated with curative intent between January 2018 and January 2025. Cases with secondary, extraskeletal, or palliative indications were excluded. Data from the institutional bone tumor registry included demographic details, tumor characteristics, treatment modalities, and survival status. Statistical analysis involved chi-squared and t-tests, with Cox proportional hazards modeling used to assess associations between clinical variables and survival. Results: Eighteen patients (mean age 13.3 years; mean follow-up 16.7 months) met inclusion criteria. Neoadjuvant chemotherapy was significantly associated with improved survival (p = 0.043). While variables such as surgical type, margin status, chemotherapy response, and metastasis at presentation did not reach statistical significance, favourable trends were observed with limb-salvage surgery, wide margins, and the OGS12 chemotherapy regimen. Cox regression revealed lower mortality hazard ratios for neoadjuvant chemotherapy (HR 0.50) and limb-salvage surgery (HR 0.32), though not statistically significant. Conclusion: Neoadjuvant chemotherapy appears to enhance survival in pediatric osteosarcoma. Though limited by sample size, this study supports its prognostic value and underscores the need for larger, prospective studies to validate these findings and inform individualized treatment strategies.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.